RIG-101 / RIGImmune - LARVOL DELTA

Leyden Labs Reports Positive Phase 1 Results for RIG-101, Supporting Advancement into Phase 2 to Protect Asthma Patients (Businesswire) - "Key findings: (i) Intranasal RIG-101 was safe and well-tolerated in healthy volunteers and patients with asthma at all dose levels with up to 7 days of daily administration; (ii) Daily intranasal dosing of RIG-101 in asthma patients produced the expected interferon response for the target antiviral mechanism of action, including inducing expression of type I and type III interferons and interferon-stimulating genes."

P1 data • Asthma

RIG 101 Trial in Healthy Adults and Adults With Asthma (clinicaltrials.gov) - P1/2 | N=82 | Recruiting | Sponsor: RIGImmune Inc.

New P1/2 trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Antiviral effects of a RIG-I agonist (RIG101) against human rhinovirus in mice and differentiated bronchial epithelium from asthmatics (ERS 2025) - "Prophylactic treatment of RIG-101 NEED TM demonstrates potent antiviral effects against HRV in vivo and i n vitro , suggesting potential utility in protecting against virally-induced asthma exacerbations."

Preclinical • Asthma • Immunology • Infectious Disease • Respiratory Diseases • CXCL10 • CXCL8

Effects of an anti-viral interferon booster, RIG-I agonist (RIG-101), on influenza infection in vitro and in vivo (ERS 2024) - "The antiviral effect was comparable or superior to oseltamivir. RIG-101 was found to show significant induction of interferon signalling, and potent antiviral effects against influenza in vitro and in vivo. This suggests that topical prophylactic treatment of RIG-101 has potential to show viral prevention efficacy against influenza infection."

Preclinical • Infectious Disease • Influenza • Novel Coronavirus Disease • Respiratory Diseases • CXCL10

Adjuvancy effects of a RIG-I agonist (RIG101) on H1N1 HA antigen intranasally vaccinated mice and human nasal epithelium/PBMCs co-culture (ERS 2024) - "RIG101, a RIG-I agonist, is promising adjuvant to boost mucosal vaccine effects against respiratory virus."

Preclinical • Infectious Disease • Inflammation • Influenza • Novel Coronavirus Disease • Respiratory Diseases

Pan-antiviral effects of RIG-I agonist (RIG-101) against respiratory syncytial virus and human rhinovirus in nasal epithelium in vitro and mice in vivo (ERS 2024) - "Prophylactic treatment of RIG-101 nanoemulsion demonstrate potent antiviral activities against HRV and RSV, suggesting that topical RIG101 delivered to nasal tract can induce sterilising immunity."

Preclinical • Asthma • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • CXCL10